The key differentiator in the business model of Krsnaa Diagnostics is the hub-and-spoke model in radiology
Representative image (AP)
PRO Only Highlights
– Quarterly performance largely backed by improved realisations
– Medium-term triggers China plus and protectionist measures for tyre industry
– Valuations not inexpensive; but improved medium-term outlook
The IPO of Krsnaa Diagnostics (Krsnaa) comes at a time when COVID-19 has forced various stakeholders to work towards accessibility and affordability of health services. It is also, interestingly, a time when we are seeing consolidation in a few spaces, such as e-pharmacy and diagnostics, like the Thyrocare-PharmEasy deal, wherein new set of investors is emerging. Company brief Incorporated in 2010, Krsnaa provides a range of diagnostic services, such as imaging/radiology and pathology. As of FY21, the company provides services in…
